NCT05987397

Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy

Clinical Multi-center Study of Mitochondrial Brain Protective Agent Idebenone in the Prevention of Post-stroke Epilepsy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,700 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

According to the random number table, all patients were divided into short-term treatment group, long-term treatment group and non-intervention stroke control group according to the proportion of (1:1:1) epilepsy disease modifier idebenone. Patients in the short-term treatment group will take idebenone for a total course of 14 days (acute period) after stroke, and patients in the long-term treatment group will take idebenone for a total course of 3 months after stroke.

Conditions

• Post Stroke Epilepsy

Interventions

Type	Name	Description
DRUG	idebenone 30 mg for 14 days	The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
DRUG	idebenone 30 mg for 3 months	The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.

Timeline

• Start date: 2023-07-05
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2023-08-14
• Last updated: 2023-08-14

Locations

1 site across 1 country: China